

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra — Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
Luxembourg Stock Exchange Bourse de Luxembourg BP 165, L-2011 Luxembourg Siege social 11, avenue de la Portal - Neuve	London Stock Exchange 10 Paternoster Square London EC4M 7LS United Kingdom

**Sub: Intimation about inadvertent typographical error in outcome of Board Meeting submitted on July 15, 2021**

Dear Sir/Madam

This is with reference to our intimation dated July 15, 2021 pertaining to the outcome of Board meeting held on July 15, 2021.

Please note that inadvertent typographical errors has been noticed in Paragraph 2 of the aforesaid intimation and accordingly the following information is being rectified through this erratum.

1. The aggregate amount for raising of funds should be read as “**Rs.500 Crores**” instead of “**Rs.504 Crores**”
2. “Enabling resolution for raising of funds by way of issue of equity shares through Preferential allotment/ Private Placement” should be read as “ **Enabling resolution for raising of funds by way of issue of equity shares through Preferential allotment/ Private Placement / Qualified Institutional Placement (QIP)** and accordingly the revised Paragraph 2 is enclosed:

“Enabling resolution for raising of funds by way of issue of equity shares through Preferential allotment/ Private Placement/**Qualified Institutional Placement (QIP)**. In this connection, please take note that the Board of Directors of the Company, at their meeting held today has approved raising of funds through issue of equity shares through preferential allotment/private placement /**Qualified Institutional Placement (QIP)** in single/multiple tranches as may be considered appropriate, subject to such approvals as may be required including the approval of Members at a General meeting further subject to such other statutory/ regulatory approvals, as applicable for an aggregate amount of upto **Rs. 500 Crores** to meet the Minimum Public Shareholding within the timelines stipulated under the Rule 19A (5) of the Securities Contracts (Regulation) Rules, 1957.”

We would request you to take the above on record and regret the inconvenience caused.

Thanking you,  
Yours faithfully,

For **Orchid Pharma Limited**

